Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Feb;41(2):345-355.
doi: 10.1007/s10875-020-00928-x. Epub 2020 Dec 1.

Impact of SARS-CoV-2 Pandemic on Patients with Primary Immunodeficiency

Samaneh Delavari #  1 , Hassan Abolhassani #  2   3 , Farhad Abolnezhadian  4 , Fateme Babaha  1   5 , Sara Iranparast  6 , Hamid Ahanchian  7 , Nasrin Moazzen  7 , Mohammad Nabavi  8 , Saba Arshi  8 , Morteza Fallahpour  8 , Mohammad Hassan Bemanian  8 , Sima Shokri  8 , Tooba Momen  9 , Mahnaz Sadeghi-Shabestari  10 , Rasol Molatefi  11 , Afshin Shirkani  12 , Ahmad Vosughimotlagh  13 , Molood Safarirad  13 , Meisam Sharifzadeh  14 , Salar Pashangzadeh  1 , Fereshte Salami  1 , Paniz Shirmast  1 , Arezou Rezaei  1 , Tannaz Moeini Shad  1 , Minoo Mohraz  15 , Nima Rezaei  1 , Lennart Hammarström  16 , Reza Yazdani  1 , Asghar Aghamohamamdi  17
Affiliations

Impact of SARS-CoV-2 Pandemic on Patients with Primary Immunodeficiency

Samaneh Delavari et al. J Clin Immunol. 2021 Feb.

Abstract

Although it is estimated that COVID-19 life-threatening conditions may be diagnosed in less than 1:1000 infected individuals below the age of 50, but the real impact of this pandemic on pediatric patients with different types of primary immunodeficiency (PID) is not elucidated. The current prospective study on a national registry of PID patients showed that with only 1.23 folds higher incidence of infections, these patients present a 10-folds higher mortality rate compared to population mainly in patients with combined immunodeficiency and immune dysregulation. Therefore, further management modalities against COVID-19 should be considered to improve the survival rate in these two PID entities using hematopoietic stem cell transplantation and immunomodulatory agents.

Keywords: COVID-19; Mortality rate; Primary immunodeficiency; Severe viral infection.

PubMed Disclaimer

Conflict of interest statement

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants, or patents received or pending or royalties.

References

    1. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382(8):727–733. doi: 10.1056/NEJMoa2001017. - DOI - PMC - PubMed
    1. Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, et al. A trial of lopinavir-ritonavir in adults hospitalized with severe covid-19. N Engl J Med. 2020. 10.1056/NEJMoa2001282. - PMC - PubMed
    1. Yao Y, Wang H, Liu Z. Expression of ACE2 in airways: implication for COVID-19 risk and disease management in patients with chronic inflammatory respiratory diseases. Clin Exp Allergy. 2020. 10.1111/cea.13746. - PMC - PubMed
    1. Djomkam ALZ, Olwal CO, Sala TB, Paemka L. Commentary: SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Front Oncol. 2020;10:1448. doi: 10.3389/fonc.2020.01448. - DOI - PMC - PubMed
    1. Shang J, Wan Y, Luo C, Ye G, Geng Q, Auerbach A, et al. Cell entry mechanisms of SARS-CoV-2. Proc Natl Acad Sci U S A. 2020;117(21):11727–11734. doi: 10.1073/pnas.2003138117. - DOI - PMC - PubMed

MeSH terms